Moderna (MRNA) analyst forecast and price target
Analyst forecast
Consensus of 27 analyst ratings
Based on 8 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Goldman Sachs | Maintained | Neutral | $137.00 from $120.00 | Oct 15, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $95.00 from $89.00 | Oct 7, 2026 |
| Citigroup | Downgraded | Neutral → Sell | $80.00 from $60.00 | Sep 30, 2026 |
| Rothschild & Co | Downgraded | Neutral → Sell | $81.00 from $40.00 | Sep 3, 2026 |
| Argus Research | Upgraded | Hold → Buy | $180.00 | Aug 28, 2026 |
| Wolfe Research | Upgraded | Underperform → Peer Perform | — | Aug 25, 2026 |
| Barclays | Maintained | Equal-Weight | $125.00 from $48.00 | Aug 24, 2026 |
| JP Morgan | Maintained | Underweight | $77.00 from $40.00 | Aug 21, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $89.00 from $39.00 | Aug 20, 2026 |
| UBS | Maintained | Neutral | $150.00 from $50.00 | Aug 20, 2026 |
| Goldman Sachs | Maintained | Neutral | $120.00 from $67.00 | Aug 20, 2026 |
| William Blair | Upgraded | Market Perform → Outperform | — | Aug 19, 2026 |
| Citigroup | Maintained | Neutral | $60.00 from $41.00 | Aug 3, 2026 |
| Goldman Sachs | Maintained | Neutral | $67.00 from $49.00 | Jul 21, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $39.00 from $33.00 | Jul 8, 2026 |
| B of A Securities | Maintained | Underperform | $38.00 from $34.00 | Jul 7, 2026 |
| RBC Capital | Maintained | Sector Perform | $45.00 from $38.00 | Jul 7, 2026 |
| Piper Sandler | Maintained | Overweight | $77.00 from $69.00 | Jun 26, 2026 |
| B of A Securities | Maintained | Underperform | $34.00 from $32.00 | Jun 8, 2026 |
| RBC Capital | Maintained | Sector Perform | $38.00 from $35.00 | May 4, 2026 |
Frequently asked questions
What is the price target for MRNA stock?
The average 12-month analyst price target for Moderna (MRNA) is $115.63, with a high estimate of $180.00 and a low of $77.00, across 8 analysts.
Is MRNA a buy, sell, or hold?
Analysts covering Moderna currently average a Hold rating: 6 buy, 15 hold and 6 sell, from 27 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for MRNA?
The average price target of $115.63 implies 51.11% downside from the last price of $236.50.
What is the latest analyst rating on MRNA?
On Oct 15, 2026, Goldman Sachs maintained Moderna at Neutral with a price target of $137.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.